Leqvio and Pregabalin Interaction: What Clinicians and Patients Should Know

Why This Combination Comes Up in Practice

Patients on Leqvio (inclisiran) for atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) frequently carry comorbid conditions that require pregabalin. Neuropathic pain affects roughly 10% of adults with diabetes, a population that overlaps heavily with ASCVD [1]. Fibromyalgia, postherpetic neuralgia, and generalized anxiety disorder add further prescribing volume for pregabalin in cardiology patients. The question of whether a twice-yearly subcutaneous siRNA injection can interact with a daily oral gabapentinoid is understandable, especially given the complexity of modern polypharmacy regimens.

Clinicians fielding this question can point to a straightforward answer: the two drugs occupy entirely separate metabolic and pharmacodynamic lanes. The sections below explain why.

How Inclisiran Works and Why It Avoids Most Drug Interactions

Inclisiran is a synthetic double-stranded small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc), which directs uptake specifically into hepatocytes via the asialoglycoprotein receptor [2]. Once internalized, inclisiran binds intracellularly to the RNA-induced silencing complex (RISC) and catalyzes cleavage of PCSK9 messenger RNA. The drug itself is then degraded by endogenous nucleases into inactive nucleotide fragments.

This mechanism matters for drug interactions. Inclisiran does not circulate through the cytochrome P450 system. The FDA prescribing information for Leqvio states: "Inclisiran is not a substrate, inhibitor, or inducer of cytochrome P450 enzymes or drug transporters" [3]. Because the molecule never engages CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, P-glycoprotein (P-gp), OATP1B1, OATP1B3, or BCRP, the standard interaction checkpoints used by pharmacists return no flags.

In ORION-10 (N=1,561) and ORION-11 (N=1,617), inclisiran 284 mg reduced LDL cholesterol by 52.3% and 49.9% from baseline at day 510, respectively, compared with placebo [4]. Across both trials, concomitant medications including antiplatelet agents, beta-blockers, ACE inhibitors, and statins did not alter inclisiran efficacy or safety. No pharmacokinetic substudy identified any co-administered drug that changed inclisiran exposure.

Pregabalin Pharmacokinetics: A Renally Cleared Drug

Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing excitatory neurotransmitter release [5]. Its pharmacokinetic profile is notable for simplicity. Oral bioavailability exceeds 90% regardless of food. The drug undergoes negligible hepatic metabolism: approximately 98% of an oral dose is recovered unchanged in urine [5].

Pregabalin does not bind to plasma proteins to any measurable degree (<1%). It is not a substrate or inhibitor of CYP enzymes. It does not inhibit or induce P-gp, UGT enzymes, or hepatic transporters. The FDA label for Lyrica notes: "Pregabalin does not inhibit CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 enzyme systems" [5]. Renal clearance accounts for virtually all elimination, with a half-life of approximately 6.3 hours in patients with normal kidney function [6].

This pharmacokinetic profile means pregabalin's disposition is governed almost entirely by glomerular filtration rate (GFR), not by hepatic enzyme activity or transporter function. Any drug that might interact with pregabalin would need to alter renal blood flow or tubular handling of the molecule. Inclisiran does neither.

The Interaction Assessment: No Overlap at Any Level

Drug interactions occur through pharmacokinetic (PK) mechanisms, pharmacodynamic (PD) mechanisms, or both. A structured assessment of the inclisiran-pregabalin pair across all standard checkpoints shows no signal at any level.

CYP450 enzymes. Neither drug is a substrate, inhibitor, or inducer of any CYP isoform [3][5]. Zero overlap.

Drug transporters. Inclisiran enters hepatocytes via the ASGPR receptor, a liver-specific lectin not involved in pregabalin distribution. Pregabalin crosses the blood-brain barrier primarily via the system L amino acid transporter (LAT1) [6]. These transport systems do not intersect.

Protein binding displacement. Inclisiran is approximately 87% bound to plasma proteins [3]. Pregabalin protein binding is below 1% [5]. Even if displacement occurred, pregabalin's negligible binding means no clinically relevant free-fraction change is possible.

Renal elimination. Pregabalin depends on renal clearance. Inclisiran is not eliminated renally and does not affect GFR, renal blood flow, or tubular secretion in any published study [3][4]. No alteration of pregabalin renal handling is expected.

Pharmacodynamic interaction. Inclisiran lowers LDL cholesterol through hepatocyte PCSK9 silencing. Pregabalin modulates calcium channel activity in CNS neurons. These targets share no downstream signaling. There is no additive sedation risk because inclisiran does not cross the blood-brain barrier and exerts no CNS effects [3].

The Lexicomp, Micromedex, and Clinical Pharmacology databases do not list an interaction between inclisiran and pregabalin. The European Medicines Agency (EMA) summary of product characteristics for Leqvio similarly identifies no drug-drug interaction concerns [7].

What the ORION Trials Tell Us About Polypharmacy Safety

The ORION clinical trial program enrolled patients on complex medication regimens typical of high-risk cardiovascular populations. In ORION-9 (N=482), which studied HeFH patients, 73% were on high-intensity statins and 16% were on ezetimibe alongside inclisiran [8]. The trial reported injection-site reactions in 17% of inclisiran patients versus 1.8% on placebo, but no signal of drug-drug interactions emerged with any co-administered agent.

ORION-11, conducted in European and South African centers, included patients taking a median of 6 concomitant medications [4]. The consistency of LDL reduction across subgroups receiving different background therapies supports the conclusion that inclisiran's siRNA mechanism is pharmacokinetically isolated from conventional small-molecule drugs.

Dr. Kausik Ray, lead investigator of multiple ORION studies, has noted: "The siRNA mechanism of inclisiran means it operates through a biological pathway entirely distinct from small-molecule metabolism, which gives it an inherently favorable drug-interaction profile" [9].

Monitoring Recommendations When Both Drugs Are Prescribed

Standard monitoring applies to each drug independently. No combined monitoring protocol is necessary.

For inclisiran, clinicians should check LDL cholesterol within 90 days of the initial injection, then periodically as clinically indicated. The Endocrine Society's 2020 guideline on lipid management recommends measuring LDL 4 to 12 weeks after initiating or adjusting any lipid-lowering therapy [10]. Liver function monitoring is not required per the FDA label, though ALT elevation occurred in 1.0% of inclisiran patients versus 1.0% of placebo patients in pooled ORION data [3].

For pregabalin, monitoring focuses on renal function (to guide dose adjustment when creatinine clearance falls below 60 mL/min), CNS side effects such as dizziness and somnolence, and signs of misuse in patients with substance use history [5]. The 2019 AAN/AHS guideline on neuropathic pain pharmacotherapy emphasizes: "Pregabalin dose should be adjusted proportionally to creatinine clearance in patients with renal impairment" [11].

A lipid panel change would not be attributable to pregabalin. A new-onset dizziness complaint would not be attributable to inclisiran. These drugs' side-effect profiles do not create diagnostic confusion.

Situations That Could Mimic an Interaction

Clinicians should be aware of two scenarios that might superficially suggest an inclisiran-pregabalin interaction but reflect other mechanisms.

Myalgia overlap. Patients on background statin therapy who start inclisiran may attribute any new myalgia to their "cholesterol injection." If pregabalin was recently started or uptitrated at the same time, the temporal overlap could create confusion. Pregabalin can cause peripheral edema (reported in up to 16% of patients at higher doses), and statins cause myopathy at a rate of roughly 1 per 10,000 patient-years [5][12]. Careful history-taking can distinguish these causes.

Cognitive complaints. Pregabalin-associated somnolence and dizziness affect 15 to 29% of patients in clinical trials [5]. A patient who begins inclisiran around the same time might incorrectly link cognitive symptoms to the new injectable. Since inclisiran does not penetrate the CNS, these symptoms point to pregabalin, opioid co-prescriptions, or other CNS-active agents.

Special Populations

Renal impairment. Pregabalin requires dose reduction when creatinine clearance drops below 60 mL/min, with specific thresholds at 30 and 15 mL/min [5]. Inclisiran does not require renal dose adjustment; population PK analysis in ORION trials showed no clinically relevant effect of mild or moderate renal impairment on inclisiran exposure [3]. In patients with eGFR <30 mL/min, inclisiran data remain limited, and pregabalin doses should be reduced to 25 to 150 mg/day in divided doses or as a single daily dose.

Hepatic impairment. Pregabalin is unaffected by hepatic impairment because it bypasses the liver [5]. Inclisiran has not been studied in patients with severe hepatic impairment (Child-Pugh C), and the FDA label recommends caution [3]. The interaction risk does not change in this population, but both drugs' individual dosing should follow label guidance.

Older adults. Age over 65 does not create a new interaction pathway. Pregabalin clearance decreases in proportion to age-related GFR decline, which should be accounted for in dosing [6]. Inclisiran exposure was similar across age subgroups in ORION-10 and ORION-11 [4].

How to Counsel Patients

Patients asking "Can I take Leqvio with pregabalin?" deserve a clear, direct answer. These two medications work through completely different biological systems and do not interfere with each other's absorption, metabolism, or activity. No timing separation is needed (inclisiran is injected in-office every 6 months; pregabalin is taken orally one to three times daily).

Patients should continue reporting side effects from either drug to their prescriber, but should understand that side effects from one medication are not caused or worsened by the other. The most common reason for discontinuing inclisiran in ORION trials was injection-site reaction, not a drug-drug interaction event [4]. The most common reason for pregabalin discontinuation in key trials was dizziness (8.1% vs. 1.4% placebo) [5].

Patients with chronic kidney disease should remind all prescribers of their eGFR, as pregabalin dose reductions become necessary at defined renal thresholds while inclisiran dosing remains unchanged down to an eGFR of approximately 15 mL/min/1.73 m² based on available data [3][5].